What cancer did keytruda demonstrate initial effectiveness?

What cancer did Keytruda first show strong results in?

Keytruda (pembrolizumab) received its first FDA approval in 2014 for advanced melanoma that could not be removed by surgery. Early trials showed clear tumor shrinkage in patients whose melanoma had stopped responding to other treatments.

How did the initial melanoma results compare to standard care?

Before Keytruda, patients with advanced melanoma often relied on ipilimumab or chemotherapy. In the first large study, Keytruda extended survival and produced higher response rates than these options, prompting regulators to grant accelerated approval.

When did Keytruda gain approval for other cancers?

After the melanoma success, the FDA added non-small cell lung cancer in 2015, then head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and microsatellite instability-high solid tumors in the following years. Each new indication built on the same PD-1 blocking mechanism.

Why are companies challenging Keytruda patents?

Merck holds multiple patents covering pembrolizumab’s composition and use. Rivals have filed challenges at the Patent Trial and Appeal Board, arguing that some claims are obvious or overlap earlier work. These disputes center on dosing schedules and combination uses rather than the original melanoma indication.

When does Keytruda’s main patent protection end?

Merck’s primary U.S. composition-of-matter patent for pembrolizumab expires in 2028, with some method-of-use patents extending to 2032–2036. Biosimilar or generic entry is unlikely before these dates unless litigation resolves earlier.

Can biosimilars reach the market before patent expiry?

Current law prevents biosimilar approval until the reference product’s exclusivity and relevant patents clear. Companies have started developing pembrolizumab biosimilars, but none can launch until at least 2028 absent a settlement or successful patent challenge.

How does Keytruda’s pricing compare to other PD-1 inhibitors?

At roughly $10,000–$12,000 per dose, Keytruda sits in the same range as Opdivo and Libtayo. Insurers often require prior authorization and step therapy, and patient-assistance programs cover copays for eligible individuals.

DrugPatentWatch.com